JP2021529780A5 - - Google Patents
Info
- Publication number
- JP2021529780A5 JP2021529780A5 JP2020573365A JP2020573365A JP2021529780A5 JP 2021529780 A5 JP2021529780 A5 JP 2021529780A5 JP 2020573365 A JP2020573365 A JP 2020573365A JP 2020573365 A JP2020573365 A JP 2020573365A JP 2021529780 A5 JP2021529780 A5 JP 2021529780A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- syndrome
- disease
- aryl
- autoimmune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862693886P | 2018-07-03 | 2018-07-03 | |
| US201862693879P | 2018-07-03 | 2018-07-03 | |
| US62/693,886 | 2018-07-03 | ||
| US62/693,879 | 2018-07-03 | ||
| US201862702621P | 2018-07-24 | 2018-07-24 | |
| US201862702602P | 2018-07-24 | 2018-07-24 | |
| US62/702,602 | 2018-07-24 | ||
| US62/702,621 | 2018-07-24 | ||
| PCT/US2019/040357 WO2020010118A1 (en) | 2018-07-03 | 2019-07-02 | Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a nlrp3 antagonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021529780A JP2021529780A (ja) | 2021-11-04 |
| JP2021529780A5 true JP2021529780A5 (https=) | 2022-07-11 |
Family
ID=67441657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020573365A Pending JP2021529780A (ja) | 2018-07-03 | 2019-07-02 | Ｎｌｒｐ３アンタゴニストを使用するｔｎｆ阻害剤に対して抵抗性の対象のための治療の方法又は治療を選択する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220339169A1 (https=) |
| EP (1) | EP3817737A1 (https=) |
| JP (1) | JP2021529780A (https=) |
| KR (1) | KR20210030947A (https=) |
| CN (1) | CN112654350A (https=) |
| AU (1) | AU2019299444A1 (https=) |
| CA (1) | CA3103664A1 (https=) |
| IL (1) | IL279889A (https=) |
| WO (1) | WO2020010118A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11370776B2 (en) | 2017-07-07 | 2022-06-28 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| CN111094242B (zh) * | 2017-07-24 | 2024-02-09 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
| US11542255B2 (en) | 2017-08-15 | 2023-01-03 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| MX2020001776A (es) | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. |
| WO2019034693A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| US11623922B2 (en) | 2017-10-03 | 2023-04-11 | Inflazome Limited | Compounds |
| KR20200087759A (ko) | 2017-11-09 | 2020-07-21 | 인플라좀 리미티드 | 신규한 설폰아마이드 카복스아마이드 화합물 |
| US12221434B2 (en) | 2017-11-09 | 2025-02-11 | Inflazome Limited | Sulfonamide carboxamide compounds |
| EP3759077A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| EP3759078A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| WO2019166632A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| US11834433B2 (en) | 2018-03-02 | 2023-12-05 | Inflazome Limited | Compounds |
| US12030879B2 (en) | 2018-03-02 | 2024-07-09 | Inflazome Limited | Sulfonyl acetamides as NLRP3 inhibitors |
| EP3823974A1 (en) | 2018-07-20 | 2021-05-26 | F. Hoffmann-La Roche AG | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| SG11202012159TA (en) | 2018-07-20 | 2021-01-28 | Hoffmann La Roche | Sulfonylurea compounds as inhibitors of interleukin-1 activity |
| WO2021002887A1 (en) * | 2019-07-02 | 2021-01-07 | Novartis Inflammasome Research, Inc. | Gut-targeted nlrp3 antagonists and their use in therapy |
| CN117105890A (zh) * | 2019-11-12 | 2023-11-24 | 成都百裕制药股份有限公司 | 酰胺衍生物及其制备方法和在医药上的应用 |
| RS65962B1 (sr) | 2020-05-08 | 2024-10-31 | Halia Therapeutics Inc | Inhibitori nek7 kinaze |
| WO2022047758A1 (en) * | 2020-09-05 | 2022-03-10 | Zhejiang University | Genetical disease modelling using mammals having nlrp3 mutation |
| JP7825294B2 (ja) * | 2021-02-10 | 2026-03-06 | ハンジョウ イノゲート ファーマ カンパニー リミテッド | Ｎｌｒｐ３阻害剤としての化合物 |
| US11932630B2 (en) | 2021-04-16 | 2024-03-19 | Novartis Ag | Heteroaryl aminopropanol derivatives |
| TWI815439B (zh) * | 2021-05-10 | 2023-09-11 | 大陸商成都百裕製藥股份有限公司 | 醯胺衍生物及其應用 |
| IL309085A (en) * | 2021-07-23 | 2024-02-01 | Novartis Ag | Dosing regimen for an nlrp3 inhibitor in the treatment of osteoarthritis |
| EP4396349A4 (en) * | 2021-09-02 | 2025-10-22 | Molecular Axiom Llc | COMPOSITIONS AND METHODS FOR MODULATING NLRP3 OR NLRP1 EXPRESSION |
| CN118302415A (zh) * | 2021-12-03 | 2024-07-05 | 辰欣药业股份有限公司 | 二甲基亚磺酰亚胺衍生物的制备方法 |
| US20230416412A1 (en) * | 2022-05-31 | 2023-12-28 | Hoffmann-La Roche Inc. | Prevention or mitigation of t-cell engaging agent-related adverse effects |
| EP4561574A1 (en) * | 2022-07-27 | 2025-06-04 | Novartis AG | Dosing regimen for a nlrp3 inhibitor |
| CN116459260A (zh) | 2023-04-28 | 2023-07-21 | 中国人民解放军空军军医大学 | 一种特异性靶向nlrp3炎症小体抑制剂的用途 |
| WO2024248287A1 (ko) * | 2023-06-01 | 2024-12-05 | 한양대학교 에리카산학협력단 | 결핵균 유래 폴리펩타이드를 포함하는 염증성 질환 치료용 약학 조성물 |
| WO2024248286A1 (ko) * | 2023-06-01 | 2024-12-05 | 한양대학교 에리카산학협력단 | 결핵균 유래 폴리펩타이드를 포함하는 암 치료용 약학 조성물 |
| TW202513060A (zh) * | 2023-09-29 | 2025-04-01 | 瑞士商諾華公司 | 用於降低心血管疾病的風險之nlrp3抑制劑 |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| WO1991003553A1 (en) | 1989-09-05 | 1991-03-21 | Immunex Corporation | TUMOR NECROSIS FACTOR-α AND -β RECEPTORS |
| TW221049B (https=) * | 1991-12-20 | 1994-02-11 | Lilly Co Eli | |
| AU670125B2 (en) | 1992-09-15 | 1996-07-04 | Immunex Corporation | Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists |
| US5705398A (en) | 1994-03-02 | 1998-01-06 | The Scripps Research Institute | Methods for identifying inhibitors of LPS-mediated LBP binding |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| MX336813B (es) | 1996-02-09 | 2016-02-02 | Abbvie Biotechnology Ltd | Anticuerpos humanos que ligan el tnfa humano. |
| EP1487457A1 (en) * | 2001-11-30 | 2004-12-22 | Pfizer Products Inc. | Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation |
| WO2005023761A2 (en) * | 2003-09-11 | 2005-03-17 | Kemia, Inc. | Cytokine inhibitors |
| WO2006133286A2 (en) * | 2005-06-07 | 2006-12-14 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Treatment of tnf antagonist-resistant inflammatory disorders and related methods |
| US8884006B2 (en) | 2011-09-19 | 2014-11-11 | University Of Puerto Rico | Small-molecule inhibitors of Rac1 in metastatic breast cancer |
| US9714288B2 (en) | 2014-09-30 | 2017-07-25 | The Regents Of The University Of California | Antisense compounds and uses thereof |
| WO2016123229A1 (en) * | 2015-01-29 | 2016-08-04 | Yale University | Compositions and methods for treating nlrp3 inflammasome-related diseases and disorders |
| KR102727059B1 (ko) * | 2015-02-16 | 2024-11-05 | 더 유니버서티 어브 퀸슬랜드 | 설포닐우레아와 관련 화합물 및 그 용도 |
| US20170145412A1 (en) * | 2015-11-04 | 2017-05-25 | Idera Pharmaceuticals, Inc. | Compositions for inhibiting nlrp3 gene expression and uses thereof |
| US20180311199A1 (en) * | 2016-01-12 | 2018-11-01 | Lawrence Chan | Combination treatment for inflammatory diseases |
| FR3046933B1 (fr) * | 2016-01-25 | 2018-03-02 | Galderma Research & Development | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires |
| US11597706B2 (en) | 2016-04-18 | 2023-03-07 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| ES2940611T3 (es) | 2016-04-18 | 2023-05-09 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP |
| US11465992B2 (en) * | 2017-07-07 | 2022-10-11 | Inflazome Limited | Sulfonamide carboxamide compounds |
| RS65492B1 (sr) * | 2017-07-24 | 2024-05-31 | Novartis Ag | Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću nlrp |
| CN111094242B (zh) * | 2017-07-24 | 2024-02-09 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
| WO2019166624A1 (en) * | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
-
2019
- 2019-07-02 CN CN201980052145.7A patent/CN112654350A/zh active Pending
- 2019-07-02 EP EP19745415.0A patent/EP3817737A1/en not_active Withdrawn
- 2019-07-02 AU AU2019299444A patent/AU2019299444A1/en not_active Abandoned
- 2019-07-02 US US17/252,630 patent/US20220339169A1/en not_active Abandoned
- 2019-07-02 KR KR1020217003092A patent/KR20210030947A/ko not_active Withdrawn
- 2019-07-02 WO PCT/US2019/040357 patent/WO2020010118A1/en not_active Ceased
- 2019-07-02 CA CA3103664A patent/CA3103664A1/en not_active Abandoned
- 2019-07-02 JP JP2020573365A patent/JP2021529780A/ja active Pending
-
2020
- 2020-12-30 IL IL279889A patent/IL279889A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021529780A5 (https=) | ||
| JP7551060B2 (ja) | プログラム可能なポリマー薬 | |
| JP7603918B2 (ja) | プログラム可能なポリマー薬 | |
| CN116583508B (zh) | 一系列哌啶取代的苯酸类化合物及其应用 | |
| JP7618137B2 (ja) | プログラム可能なポリマー薬 | |
| CA3103664A1 (en) | Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a nlrp3 antagonist | |
| US12486278B2 (en) | MASP-2 inhibitors and methods of use | |
| JP6920202B2 (ja) | Ｉｒａｋ阻害剤としてのピリダジノン大環状化合物及びその使用 | |
| JP7721142B2 (ja) | Ｍａｓｐ－２阻害剤および使用方法 | |
| JP2022505525A5 (https=) | ||
| KR20250007056A (ko) | 악성 종양 치료용 제제 및 조성물 | |
| US12110288B2 (en) | MASP-2 inhibitors and methods of use | |
| AU2023266363A1 (en) | MASP-2 inhibitors and methods of use | |
| AU2013351622A1 (en) | Heteroaryl alkyne compound and application thereof | |
| AU2013227024A1 (en) | Novel piperidine compound or salt thereof | |
| JP7058322B2 (ja) | 細菌感染症を治療するための化合物および方法 | |
| JP2023509442A5 (https=) | ||
| JP2025521156A (ja) | Ｄｎａポリメラーゼシータ阻害剤としてのチアジアゾリル誘導体およびその使用 | |
| US20240336606A1 (en) | Substituted benzo or pyridopyrimidine amine inhibitor, preparation method therefor, and application thereof | |
| WO2024140923A1 (zh) | Prmt5-mta抑制剂 | |
| KR20170005868A (ko) | S100-저해제로서 유용한 새로운 화합물 | |
| JP7731151B2 (ja) | トリアゾロピラジン系化合物及びその用途 | |
| US20250263383A1 (en) | Novel inhibitors of guanosine monophosphate synthetase as therapeutic agents | |
| WO2025166260A1 (en) | Amide substituted tricyclic guanidino compounds as prmt5 inhibitors | |
| WO2016050201A1 (zh) | 高选择性取代嘧啶类pi3k抑制剂 |